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Optimizing Randomized Trial Designs to
Distinguish which Subpopulations Benefit
from Treatment
Michael Rosenblum and Mark J. van der Laan
Abstract
It is a challenge to evaluate experimental treatments where it is suspected that
the treatment effect may only be strong for certain subpopulations, such as those
having a high initial severity of disease, or those having a particular gene vari-
ant. Standard randomized controlled trials can have low power in such situations.
They also are not optimized to distinguish which subpopulations benefit from a
treatment. With the goal of overcoming these limitations, we consider random-
ized trial designs in which the criteria for patient enrollment may be changed, in
a preplanned manner, based on interim analyses. Since such designs allow data-
dependent changes to the population sampled, care must be taken to ensure strong
control of the familywise Type I error rate.
Our main contribution is a general method for constructing randomized trial de-
signs that (1) allow changes (based on a prespecified decision rule) to the popula-
tion enrolled based on interim data, (2) make no parametric model assumptions,
and (3) guarantee the asymptotic, familywise Type I error rate is strongly con-
trolled at a specified level. As a demonstration of our method, we prove new,
sharp results for a simple, two-stage enrichment design. We then compare this
design to a fixed design, focusing on each design’s ability to determine overall
and subpopulation specific treatment effects.
1 Introduction
Randomized trial designs in which participants are enrolled sequentially over time, and
where interim analyses are done at prespecified points during the trial, are called “group
sequential designs.” We consider settings where follow up time is relatively short. At in-
terim analyses, it is then possible to look at outcome data from the patients who have
already completed the trial, and use this to optimize aspects of the trial design.
We focus on designs that allow preplanned changes to the population enrolled, based
on interim analyses. Such designs, called “enrichment designs,” may be useful when it is
thought that the effect of a treatment may differ in certain subpopulations. For example,
these could be subpopulations defined by a genomic biomarker measured at baseline such
as HER2 in studies of breast cancer therapies (Baselga, 2001; Wang et al., 2007, 2009), or
defined by baseline factors such as initial severity of depression in studies of antidepres-
sants (Kirsch et al., 2008). In both examples, there is evidence that certain subpopulations
(those with higher levels of HER2 overexpression, and those with high baseline severity
of depression, respectively) may benefit more from specific interventions. As we show be-
low, designs that allow preplanned changes to which subpopulations are enrolled can lead
to more power, and can reveal more information about subpopulation specific treatment
effects.
As a concrete example, consider designing a study to test the effectiveness of a hypo-
thetical new antidepressant. Kirsch et al. (2008) present suggestive, though not conclusive,
evidence that certain commonly prescribed antidepressants may only be effective for those
with severe (rather than moderate) depression at study baseline. With this in mind, it may
be advantageous to incorporate the following preplanned interim analysis in one’s trial of
the new antidepressant: if it is observed that the treatment effect is sufficiently low among
those with moderate baseline depression, one will enroll only (or more intensely) those
with severe baseline depression for the rest of the trial. We show in Section 4 that cer-
tain designs of this type can give improved power, compared to a standard fixed design, at
certain alternatives of interest. Due to the multiple hypotheses potentially tested in an en-
richment design, a major methodological challenge for such designs is guaranteeing strong
control of the familywise Type I error rate.
Our main contribution is a general method for computing the asymptotic, worst-case,
familywise Type I error rate for a wide range of enrichment designs. This is of interest, in
particular, to the U.S. Food and Drug Administration, who state in a recent draft guidance
(FDA, 2010) that for trials allowing certain interim modifications such as those discussed in
this paper, “The chief concerns with these designs are control of the study-wide Type I error
rate, minimization of the impact of any adaptation-associated statistical ... or operational
bias on the estimates of treatment effects, and the interpretability of trial results.” We focus
throughout this paper on strong control of the familywise Type I error rate, as defined by
(Hochberg & Tamhane, 1987, pp. 3, 7), and only consider designs that guarantee clear
interpretability of trial results. We briefly discuss the important topics of estimation and
confidence intervals in Section 6.
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The familywise Type I error rate is the probability that at least one true null hypothesis is
rejected. Throughout, we slightly abbreviate “familywise Type I error rate” by “familywise
Type I error.” The worst-case, familywise Type I error is the supremum over all possible
data generating distributions of the familywise Type I error. The asymptotic, worst-case,
familywise Type I error is the limit of this supremum as sample sizes in all stages of a given
design go to infinity, which we formally define in Section 5.4; we also define strong control
of asymptotic, familywise Type I error in Section 5.4.
Even in some relatively simple enrichment designs, such as those we present in Sec-
tion 3, it is difficult or impossible to analytically determine the asymptotic, worst-case,
familywise Type I error. To address this, we present a general theorem that reduces this
problem for a given design to a more convenient optimization problem, that often can be
exactly solved by standard software. We apply this theorem to the class of enrichment
designs in Section 3, leading to new (to the best of our knowledge) results on familywise
Type I error control for these designs.
Throughout this paper, we only consider designs with preplanned rules for changing
the population enrolled, based on interim data. We do not consider designs that adapt the
total sample size, the number of treatment arms, or the randomization probabilities, for
example. However, it is possible to apply our general method to designs that involve such
adaptations, and this is an area for future research.
The outline of the paper is as follows. We present related work in Section 2. Then, in
Section 3, we give a class of two-stage enrichment designs that will be used as an illustra-
tion throughout the paper. In Section 4, we present a simulated application of a particular
enrichment design from Section 3. The simulation is based on a meta-study of certain an-
tidepressants (Kirsch et al., 2008), and the goal is to compare the performance of the enrich-
ment design to a fixed design, in determining overall and subpopulation specific treatment
effects. Next, in Section 5, we give the details of our general method and present our main
theorem; we then apply it to prove new, sharp results for the class of enrichment designs
from Section 3. We discuss limitations of our approach and open problems in Section 6.
2 Related Work
Methods have been proposed to deal with the multiple testing problem that arises from
design adaptations in which the study population, study treatment, or study endpoint may
be changed, e.g. (Thall et al., 1988; Schaid et al., 1990; Bauer & Ko¨hne, 1994; Follmann
et al., 1994; Follmann, 1997; Kieser et al., 1999; Hommel, 2001; Stallard & Todd, 2003;
Sampson & Sill, 2005; Bischoff & Miller, 2005; Jennison & Turnbull, 2006, 2007; Wang
et al., 2007, 2009). In many cases these methods lead to sharp bounds on familywise Type
I error. However, for the class of designs we give in Section 3 these methods either do not
apply or our method gives improved results.
Below, we describe the following related work that is especially relevant to the class
of designs we present in Section 3: (Thall et al., 1988; Bauer & Ko¨hne, 1994; Follmann,
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1997; Kieser et al., 1999; Wang et al., 2007, 2009). Each of these papers incorporates a
preplanned interim analysis that can result in a change in the data generating distribution
for the second stage, and a method for ensuring familywise Type I error is controlled.
Thall et al. (1988) consider the problem of estimating the effect of the best treatment
among a set of k prespecified treatments. They use a two stage design that drops all but the
single best performing treatment after an interim analysis. Their method can be modified to
apply in the setting of this paper, where rather than selecting which treatment to continue in
stage two, we select which population to continue enrolling in stage two. This modification
of the Thall et al. (1988) procedure to our setting, however, differs from the new class of
adaptive designs we present in Section 3, in two ways. The design of Thall et al. (1988)
does not allow the option of continuing to sample from both populations in stage two, and
it uses a different final test statistic than we do.
Bauer & Ko¨hne (1994) and Kieser et al. (1999) present a general multiple testing pro-
cedure that can be applied to designs where the subpopulations enrolled can be changed
based on interim analyses. This procedure is an important advance, and is based on the
closed testing principle (Marcus et al., 1976), as well as combining p-values from each
stage using a prespecified combination rule. Application of their method to our class of
designs in Section 3, however, gives a multiple testing procedure with strictly lower power
than the one resulting from application of our general method from Section 5.
Follmann (1997) proves control of Type I error for a large class of useful enrichment
designs. This class of designs allows a much wider range of decision rules than the ones we
consider in Section 3. However, in (Follmann, 1997), the only null hypothesis tested is the
global null hypothesis that neither subpopulation benefits from treatment. In contrast, we
test null hypotheses corresponding to the overall population as well as specific subpopula-
tions. The advantage of testing more than the global null hypothesis is that rejecting it does
not permit one to draw conclusions about treatment effects in a specific subpopulation or
in the total population. This is because the complement of the global null hypothesis is that
there is a positive effect in at least one subpopulation; without further tests or assumptions,
one cannot directly conclude which subpopulation this is, nor determine whether there is a
net positive effect in the total population.
Wang et al. (2007, 2009) propose important enrichment designs using decision rules
similar to those we give in Section 3. However, in (Wang et al., 2007), the focus is on
testing the null hypothesis associated with a single subpopulation; their designs have more
power than ours for detecting an effect in this single subpopulation, but less power than our
method for testing the null hypothesis for the total population. The setup in Wang et al.
(2009) differs from ours in that they assume if there is no net positive effect in the overall
population, then there is no net positive effect in a certain, prespecified subpopulation; we
do not make that assumption here.
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3 A Class of Enrichment Designs
3.1 Overview
We present a class of two stage, enrichment designs tailored to the problem described
in Section 1, of testing the effectiveness of a hypothetical new antidepressant. The aim of
these designs is to improve power and better determine subpopulation specific treatment ef-
fects. We show how our general method gives the first (to the best of our knowledge) means
of precisely computing the asymptotic, worst-case, familywise Type I error of these en-
richment designs. This can be used to determine the subclass of such designs that strongly
control familywise Type I error at a desired level (e.g. 0.05); we can then compare these
designs to standard fixed designs in terms of overall power and ability to determine sub-
population specific treatment effects. Later, in Section 4, we present a simple enrichment
design from our class that improves on a standard fixed design at certain alternatives of
interest.
As described above, Kirsch et al. (2008) present suggestive, but not conclusive, ev-
idence from a meta-analysis that a class of commonly used antidepressants may not be
superior to placebo for those with moderate pretreatment depression (though this is based
on only one study), while they are superior to placebo for those with severe pretreatment
depression (based on 34 studies). We consider a method for designing a trial of a hypothet-
ical new antidepressant with this in mind.
For each subject, the Hamilton Rating Scale of Depression (HRSD) score is recorded
at baseline and after a set period of time. Lower HRSD scores indicate lower severity of
depression. For each subject, we define his/her improvement in HRSD score to be baseline
score minus end of study score. (If a subject’s HRSD score increases by the end of study,
his/her improvement has a negative value.)
We refer to the set of subjects with moderate depression at baseline as “subpopulation
1” and refer to the set of subjects with severe depression at baseline as “subpopulation 2.”
We refer to the union of subpopulations 1 and 2 (i.e. those with either moderate or severe
pretreatment depression) as the “total population.” Let H01 denote the null hypothesis that
for subpopulation 1, the mean improvement in HRSD score under the new treatment is
less than or equal to the mean improvement in HRSD score under the placebo. In an
analogous manner, define the null hypothesis H02 corresponding to subpopulation 2, and
the null hypothesis H03 corresponding to the total population. The alternative hypotheses
are that the mean HRSD score improvement under treatment is greater than under placebo,
for subpopulation 1, for subpopulation 2, and for the total population, respectively. Though
our designs are motivated by the above application, they can be useful in many situations
where the population enrolled consists of two non-overlapping subpopulations of interest
(e.g., defined in terms of a genetic marker, or a risk score at baseline).
Each participant enrolled is randomly assigned to the study arm or the control arm
with 50% chance of being assigned to each. For simplicity, we assume exactly 50% of
participants in each subpopulation are assigned to each arm, which can be approximately
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ensured using stratified block randomization. At the end of stage one, we compute three
z-statistics, T (1)1 , T
(1)
2 , T
(1)
3 (defined formally below), corresponding to the standardized dif-
ference in mean HRSD improvement between treatment and control groups for subjects in
subpopulation 1, subpopulation 2, and the total population, respectively. We assume that
data on all subjects from stage one are available at the interim analysis.
We allow a decision to be made at the end of stage one, based on a prespecified decision
rule. We denote this decision rule, which maps the data collected in stage one to a choice
for how many subjects from each subpopulation to sample in stage two, by D. We consider
a class of decision rules, which we denote by D, that are Borel measurable maps from the
above stage one statistics to the following two choices for the subpopulation(s) to enroll in
stage two:
(i) Continue enrolling from both subpopulations in the same proportions as in stage one,
or
(ii) Enroll only from the subpopulation s ∈ {1, 2} corresponding to the larger of the
stage one z-statistics T (1)1 , T
(1)
2 . (Any ties could be decided arbitrarily based on a
prespecified rule.)
One example of a decision rule in the class D is to always choose option (ii), that
is, to always sample in stage two only from the subpopulation with larger z-statistic from
stage one. Another example of a decision rule in the class D is to use option (i) if the z-
statistic T (1)3 for the total population is above a prespecified threshold, and to use option (ii)
otherwise. Figure 1 gives a flow chart representing this type of decision rule. The standard
fixed design, which corresponds to always choosing option (i), is also a decision rule in the
class D.
At the end of the trial, a preplanned final test statistic is computed (defined below),
leading to possible rejection of one of the null hypotheses {H01, H02, H03}. This final test
statistic is a weighted combination of the z-statistic T (1)3 from the first stage (using all first
stage data from both subpopulations) and the z-statistic from the second stage (using all
second stage data). If the final test statistic exceeds a threshold c, we reject the null hypoth-
esis corresponding to the subpopulation (or the total population) selected for enrollment in
stage two.
3.2 Formal definition of statistics, assumptions, and testing procedure
We now precisely define the statistics used in the above decision rules and to test the family
of null hypotheses {H01, H02, H03}. We denote the data for subjectm by (Im, Sm, Am, Ym),
which includes the stage the subject entered the trial (Im ∈ {1, 2}), the subject’s subpopu-
lation (Sm ∈ {1, 2}), the subject’s study arm assignment (Am ∈ {0, 1}), and the subject’s
outcome (Ym ∈ R), respectively.
We assume in each stage, for each subpopulation sampled in that stage, that an equal
number are assigned to each study arm (though it is possible to relax this assumption). We
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Enroll from:
Subpopulation 1
Subpopulation 2
Subpopulation 1
Subpopulation 2
Else, if estimated treatment effect
stronger in subpopulation 1
If estimated treatment effect
strong in total population
Else, if estimated treatment effect
stronger in subpopulation 2
Subpopulation 1
Subpopulation 2
Decision Stage 2
Enroll from:
Generic Enrollment Procedure for Enrichment Design
Stage 1
Figure 1: A flow chart depicting a type of enrichment design within our
class, where enrollment in stage two can be restricted to the subpopulation
with larger z-statistic based on data from stage one. Each labeled box rep-
resents a set of patients enrolled from a certain subpopulation.
assume for each subject, that conditioned on the subject’s subpopulation s and study arm
assignment a, his/her outcome Y is drawn from an unknown data generating distribution
Qsa independent of the other subjects’ data. The only assumptions we make on the data
generating distributions Qsa are that there exists a γ > 0 and M > 0 that do not depend on
sample size, such that the support of Qsa is on [−M,M ] and the variance σ2(Qsa) of Qsa
is at least γ.
Let ni denote the total number of subjects in stage i, which is preplanned. We require
that the fraction of subjects in the first stage n1/(n1 +n2) be at least 0.05 and at most 0.95.
We also make an assumption about the fraction of stage one subjects who are from each
subpopulation s ∈ {1, 2}, which we denote ps. We consider each ps fixed (non-random)
and unknown, since in practice one may not know in advance how many subjects will
enroll from each subpopulation. However, we assume there is a non-negligible fraction
of subjects in stage one from each subpopulation; that is, we assume for some τ > 0 not
depending on the sample size, that for each s, ps > τ .
Let T(1) = (T (1)1 , T
(1)
2 , T
(1)
3 ) denote the stage one z-statistics for subpopulation 1, sub-
population 2, and the total population, respectively, defined as
T
(1)
1 =
∑
m:Im=1,Sm=1
[(YmAm − Ym(1− Am)]/se1, (1)
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T
(1)
2 =
∑
m:Im=1,Sm=2
[(YmAm − Ym(1− Am)]/se2, (2)
T
(1)
3 =
∑
m:Im=1
[(YmAm − Ym(1− Am)]/se3, (3)
where the sei are defined by
se1 =
√
(n1p1/2)σ2(Q10) + (n1p1/2)σ2(Q11), (4)
se2 =
√
(n1p2/2)σ2(Q20) + (n1p2/2)σ2(Q21), (5)
se3 =
√
se21 + se22. (6)
Here, sei is the standard error for the corresponding sum in the definition of T
(1)
i , condi-
tioned on sample sizes in each subpopulation and treatment category. For simplicity we
assume these variances are known, though we allow them to differ by subpopulation and
treatment category. It is possible to extend our results to the more realistic case where these
variances are estimated.
We now describe the final test statistic and the rejection region for each null hypothesis.
After stage two is completed, we compute the following z-statistic based on all the data
from that stage:
T (2) =
∑
m:Im=2
[YmAm − Ym(1− Am)]/se4, (7)
where se4 is the standard error for the corresponding sum, conditioned on the enrollment
decision made just after stage one, defined analogously as (4), (5), and (6); we defer the
formal definition of se4 to Section C of the Supplementary Material.
We reject the null hypothesis H0j corresponding to the subpopulation (or the total pop-
ulation) enrolled in stage two, if the following weighted combination of z-statistics from
both stages: √
n1/(n1 + n2)T
(1)
3 +
√
n2/(n1 + n2)T
(2), (8)
exceeds c for some prespecified threshold c. That is, if only subpopulation 1 is enrolled in
stage two and (8) exceeds c, we reject H01; if only subpopulation 2 is enrolled in stage two
and (8) exceeds c, we reject H02; if both subpopulations are enrolled in stage two and (8)
exceeds c, we reject H03.
We define our class of enrichment designs to be those that use a decision rule D ∈ D,
the z-statistics defined above, and the rejection rule defined in the previous paragraph.
3.3 Application of general method from Section 5 to above class of
designs
The general method we present in Section 5 allows one to compute, for each enrichment
design in the class defined above, the minimum threshold value c in (8) that guarantees
strong control of the asymptotic, familywise Type I error at a given level α. This is useful
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since it is quite difficult, if not impossible, to determine this minimum threshold value c
analytically. Our general method gets around this obstacle by reducing this problem to an
optimization problem that can be solved numerically with standard software, to any desired
precision. This general method can be applied to a wide variety of designs, not only to those
considered above.
We obtain, as shown in Section 5 and Sections B-E of the Supplementary Material, that
under the above assumptions, for any decision rule D ∈ D, that the minimum threshold
value c that guarantees strong control of the asymptotic, familywise Type I error at level
α = 0.05 is Φ−1(0.95), for Φ the cumulative distribution function of the standard normal.
This is exactly the same threshold as would have been used in a standard fixed design,
with no preplanned change. This is surprising, since allowing designs that adapt to accrued
data has the potential to result in Type I error inflation. We show for the above class
of enrichment designs that no such inflation can occur, at least asymptotically. Thus, the
above class of designs allows flexibility at no price in terms of a stricter rejection threshold.
Furthermore, in Section 4 we show one such design that provides a substantial gain in
the probability of correctly detecting an effect when it exists in just one subpopulation,
compared to a fixed design (though there is some price paid when there is an effect in both
subpopulations).
In the above class of enrichment designs, all the first stage data (from both subpopula-
tions) is used in the final test statistic (8), even when the final hypothesis tested concerns
only one of these subpopulations. Though this may initially appear odd, since data from
one subpopulation may influence whether the null hypothesis for the other subpopulation
is rejected, this is a property shared by virtually all procedures for controlling familywise
Type I error (except the conservative procedure of Bonferroni); for example, this property
holds for the closure principle of Marcus et al. (1976), the step-down procedure of Holm
(1979), and the step-up procedure of Hochberg (1988).
To explain the intuition behind why the above class of designs can be advantageous,
consider the case where subpopulation 2 (those with severe baseline depression) has the
larger corresponding z-statistic in stage one, and enrollment is from only this subpopula-
tion in the second stage. Then the null hypothesis tested at the end of the study is H02,
the null hypothesis of no mean treatment effect in subpopulation 2. If we were to test H02
based only on the data from subpopulation 2 (thereby throwing out the stage one data for
subpopulation 1), this would introduce a selection bias due to essentially hiding data that
was unfavorable. A correction can be done to account for this, by raising the threshold that
the final test statistic must exceed before the null hypothesis H02 is rejected, as is done in a
similar situation in (Thall et al., 1988). In contrast, our testing procedure does not require
any such raised threshold; the reason, intuitively, is that our test statistic already includes
the penalty of having to incorporate data from the subpopulation that had a weaker signal.
This intuitive argument is proved rigorously in Sections B-E of the Supplementary Mate-
rial. It is an area of further research to compare our designs to ones that throw out data from
discontinued subpopulations and correct for the resulting selection bias by incorporating a
prespecified penalty.
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4 Power Comparison between adaptive design from Sec-
tion 3 and a standard fixed design
We show in Section 5 and Sections B-E of the Supplementary Material that for each deci-
sion rule in the classD given above, the resulting adaptive design guarantees strong control
of asymptotic, familywise Type I error at level α = 0.05, when the rejection threshold c
for the final statistic (8) is set to Φ−1(0.95). Having shown the validity of such enrichment
designs in terms of Type I error control, we now consider their power. We present a par-
ticular design from the class D, and compare its power to that of a standard fixed design,
under several scenarios. We continue to use the example of testing a hypothetical new an-
tidepressant. We are motivated by the meta-analysis of Kirsch et al. (2008), who present
suggestive, but not conclusive, evidence that a class of antidepressants may not be supe-
rior to placebo for those with moderate pretreatment depression (subpopulation 1 in what
follows), while they are superior to placebo for those with severe pretreatment depression
(subpopulation 2 in what follows).
To specify a particular adaptive design from the class in the previous section, we need
to choose a decision rule D ∈ D. Recall that each D ∈ D is a function from the stage one
statistics to two possible choices for stage two enrollment: (i) enroll from both subpopula-
tions as in stage one or (ii) enroll only from the subpopulation corresponding to the larger
of the stage one z-statistics T (1)1 , T
(1)
2 . We define our decision rule D to choose option (i)
if the z-statistic T (1) > T (2) or T (1) > 0.2, and option (ii) otherwise.
The intuition behind our choice of decision rule is that if T (1) > T (2) or T (1) > 0.2,
then there is at least some hope that the treatment is effective for subpopulation 1 (those
with moderate pretreatment depression), and so we continue enrolling them (as well as
those from subpopulation 2) in stage two. Otherwise we give up on subpopulation 1 and
only enroll from subpopulation 2 for the rest of the trial. We next explain how we chose
the threshold of 0.2.
Since the above design is in the class D, the asymptotic, familywise Type I error is
strongly controlled, as described above. Consider replacing the threshold 0.2 above by any
other prespecified threshold. Since the resulting design remains in the class D, the same
familywise Type I error guarantee holds. It is therefore possible to examine various thresh-
old values, and select based on which one gives the most power in scenarios of interest.
We selected the threshold 0.2 to give a good tradeoff in power in the scenarios considered
below.
In Section G of the Supplementary Materials we compare the familywise Type I error
and power of this enrichment design to a standard fixed design, under a variety of scenarios.
We present five such scenarios here, which we number 1a, 1b, 2a, 2b, and 3. In all scenarios,
we assume that in stage one, equal numbers are enrolled from each subpopulation.
In scenarios 1a and 1b, we use data generating distributions for each subpopulation
constructed to reflect what was seen in the meta-analysis of Kirsch et al. (2008), i.e. no
effect of the treatment compared to placebo in those with moderate initial depression, but
a mean improvement r > 0 comparing treatment vs. placebo in those with severe initial
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depression. In scenario 1a, this mean improvement r is set to be 1.8 HRSD points, which
is the point estimate of this quantity in (Kirsch et al., 2008); in scenario 1b, the mean
improvement r is set to the more optimistic value of 3 HRSD points, which was seen in
(Kirsch et al., 2008) for subjects with very severe initial depression.
In scenarios 2a and 2b, we use data generating distributions where the treatment is
equally effective for both subpopulations. The mean improvement r′ in treatment over
placebo is set to 1.8 HRSD points in scenario 2a, and 3 HRSD points in scenario 2b.
Lastly, in scenario 3, we use data generating distributions where there is no effect in any
subpopulation, so we can assess Type I error of the adaptive and fixed designs.
Other parameters of the data generating distributions, such as the variance in each arm,
were based on the estimates of these quantities in Kirsch et al. (2008). Total sample size
was fixed in all the scenarios at 488 subjects, which was chosen to provide 80% power to
the fixed design under scenario 2a. For each scenario, and for each of the two trial designs
(adaptive and fixed), 100,000 simulated trials were run. See Section F of the Supplementary
Materials for full details of how the data generating distributions for each scenario are
defined, and for the R code used in the simulations.
Ad. Fix. Ad. Fix. Ad. Fix. Ad. Fix. Ad. Fix.
Probabilities of Rejecting Null Hypotheses H02, H03,
 Comparing Adaptive to Fixed Designs, 
 Under Scenarios 1a, 1b, 2a, 2b, 3.
Scenario 1a                 Scenario 1b               Scenario 2a               Scenario 2b                Scenario 3    
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Figure 2: For each of five scenarios, we compare the performance of the
adaptive (abbreviated “Ad.”) to fixed (abbreviated “Fix.”) designs. In each
comparison, we depict the probability of rejecting each of the null hypothe-
ses H02 and H03, which are both false in all scenarios except scenario 3. By
construction, neither of the designs ever rejects H01.
In each scenario, for both the adaptive design and fixed design, the proportion of
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simulated trials leading to rejection of each null hypothesis (among H01, H02, H03) was
recorded. Figure 2 shows, for each scenario, side-by-side bar plots of the probability that
each null hypothesis is rejected; the bar on the left is for the adaptive design, and the bar
on the right is for the fixed design. For the adaptive design we are considering, which by
construction can lead to rejection of exactly one of the null hypotheses H02, H03 (or no
rejection at all), the corresponding bar is shaded to reflect the proportion of simulated trials
in which each null hypothesis is rejected; the length of the striped part of the bar is the pro-
portion of simulated trials in which H02 is rejected, and the length of the solid black part of
the bar is the proportion of simulated trials in which H03 is rejected. In contrast, since the
fixed design can only lead to rejection of H03 (or no rejection at all), the corresponding bar
is always shaded solid black corresponding to rejecting H03.
Consider the five scenarios depicted in Figure 2, from left to right. We call the prob-
ability of rejecting at least one of H02, H03 when both are false (which is the case in all
scenarios except scenario 3) the “overall power.” In scenarios 1a and 1b, where the treat-
ment is only effective for subpopulation 2, the adaptive design has more overall power than
the fixed design, by 14% and 20%, respectively. In scenarios 2a and 2b, where the treat-
ment is equally effective for both subpopulations, the overall power is roughly equal for
both designs; however, the adaptive design fails to reject H03 more often, by 8% and 3%,
respectively. In scenario 3, where the treatment has no effect for either subpopulation, Type
I error is 0.05 for both designs.
We summarize the tradeoff involved in using the adaptive vs. fixed design, in the sce-
narios considered above. The adaptive design allows potential gains of 14%-20% in overall
power in the scenarios where the treatment only works for those with severe pretreatment
depression (subpopulation 2). In the scenarios where the treatment is equally effective for
both subpopulations, the overall power of the two designs is roughly the same, but the
adaptive design leads to potential losses of 3%-8% in ability to reject the null hypothesis
H03 for the total population.
It is possible to augment both the above adaptive design and fixed design to include a
subsequent test of the null hypothesis H02 whenever H03 is rejected, in a way that leads to
no inflation of asymptotic, worst-case, familywise Type I error. We do not consider such
designs here, though comparisons of such designs are an important area for future research.
5 General Method and Theorem
5.1 Overview
Our main theorem allows one to reduce the problem of computing the asymptotic, worst-
case, familywise Type I error of a wide variety of hypothesis tests in adaptive designs to a
manageable optimization problem. Before presenting our main theorem, we describe the
following: the components of the design that must be prespecified; the data generating
distributions and statistical model; the definition of asymptotic, worst-case, familywise
Type I error; our assumptions on the statistics used; and the intuition behind the theorem.
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After presenting our theorem, we show how it is applied to the class of enrichment designs
from Section 3 to precisely characterize the asymptotic, worst-case, familywise Type I error
for these designs.
We focus only on two stage designs below, for clarity. It is straightforward to gener-
alize these definitions, assumptions, and our main theorem to designs with any number of
stages. The theorem below can be easily generalized to apply to designs that incorporate
adaptations in addition to changing the population sampled, such as changes to sample size
and to randomization probabilities, but we do not present such designs here.
5.2 Items requiring prespecification
We require the following to be prespecified in any design we consider:
1. a finite set of subpopulations of interest S, and a finite set of treatment arms A.
2. the total number of subjects to be enrolled in each stage i, denoted by ni. We assume
there is a positive constant r, independent of sample size, such that n2 = brn1c. We
let n = (n1, n2).
3. for each stage i, a vector T(i) of statistics taking values in Rti , for some ti. Each T(i)
is a function only of the stage i data and the enrollment decisions made before stage
i.
4. a randomization procedure, specifying the probability that each subject is assigned
to each treatment arm. We allow this procedure to be standard randomization, block
randomization, stratified randomization, or an adaptive method of randomization.
5. a finite set E of potential enrollment procedures for stage two, each of which specifies
the proportion of stage two subjects to enroll from every subpopulation. We assume,
for each enrollment procedure in E , that one can enroll in stage two to exactly achieve
these proportions.
6. a decision function (or rule) D that maps each value of the vector of stage one statis-
tics T(1) to an element in the set E of potential enrollment proportions for each sub-
population for stage two. We restrict the complexity of the decision rule in the fol-
lowing sense: we require that for each possible enrollment procedure  ∈ E , the set
of values D−1() of the statistics T(1) leading to this choice is a finite union of Borel
measurable, convex subsets of Rt1 .
7. A set of null hypotheses H0 = {H0j}j∈J to be tested, and for each one, a corre-
sponding rejection region Rj ⊆ Rt1+t2 . Each null hypothesis H0j represents the
subset of the possible data generating distributions Q (defined below) for which this
null hypothesis is true. We denote the set of rejection regions for the null hypothe-
ses by R = {Rj}j∈J , and require that each rejection region Rj is a finite union of
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Borel measurable, convex subsets of Rt1+t2 . At the end of study, we reject all null
hypotheses H0j for which
(
T(1),T(2)
) ∈ Rj .
5.3 Data generating distributions and statistical model
We assume that for each subject, conditioned on the subject’s subpopulation s and study
arm assignment a, his/her outcome Y is a random draw from an unknown data generating
distribution Qsa. We assume each such random draw is independent of the subpopulations,
treatment assignments and outcomes of all the other subjects. For ease of reference, we
denote the set of data generating distributions Qsa by Q′ = {Qsa}a∈A,s∈S . We assume that
Q′ is an element of a statistical model Q′. This may be a nonparametric model, such as
the one specified in Section 3.2 (which puts no constraints on each Qsa except for having
bounded support and a minimum variance), a semiparametric model, or a parametric model.
Denote the fraction of stage one subjects who are from subpopulation s ∈ S by ps,
which we allow to be unknown before the trial starts. We denote the set of subpopulation
proportions enrolled in stage one by p = {ps}s∈S . Let p denote the set of possible p. This
could be unconstrained, or constraints can be imposed based on knowledge of possible
enrollment proportions.
The joint distribution of the statistics T =
(
T(1),T(2)
)
, which we denote by P (n), is
a function of the data generating distributions Q′, the stage one subpopulation proportions
p, and the sample size n. Implicitly, P (n) also depends on the prespecified quantities listed
in Section 5.2, including the set of subpopulations S , the set of treatments A, the possible
enrollment procedures for stage two E , the definition of the statistics T, and the decision
rule D.
To simplify notation in what follows, we bundle Q′ and p together and denote the pair
(Q′, p) by Q. We let Q denote Q′ × p, which represents the class of all possible data
generating distributions and stage one subpopulation enrollment proportions (though we
refer to each Q ∈ Q below, for brevity, as a “data generating distribution”).
5.4 Definition of asymptotic, worst-case, familywise type I error
The main problem addressed in this paper is to compute the asymptotic, worst-case fami-
lywise Type I error for a given design. The familywise Type I error at sample size n, and
data generating distribution Q ∈ Q, is
P (n)
T ∈ ⋃
j:Q∈H0j
Rj
 . (9)
Hosted by The Berkeley Electronic Press
The worst-case, familywise Type I error is defined as the supremum over Q ∈ Q of (9).
The asymptotic, worst-case, familywise Type I error is defined as
lim sup
n→∞
sup
Q∈Q
P (n)
T ∈ ⋃
j:Q∈H0j
Rj
 ,
where n→∞ is shorthand for n1, n2 →∞, under the constraint given above in Section 5.2
that n2 = brn1c for some positive constant r. We say the asymptotic, familywise Type I
error is strongly controlled at level α if the above expression is at most α.
Having the supremum over Q ∈ Q nested inside the limit as n goes to infinity, allows
for different sets of distributions to have the worst-case, familywise Type I error at each
sample size n. Designs in which asymptotic, worst-case familywise Type I error is at most
0.05 guarantee control over familywise Type I error, uniformly over the data generating
distributions, as sample size grows to infinity, which is a desirable property.
5.5 Assumptions on statistics
In our theorem below, we make two assumptions on the distributions of the statistics T.
These assumptions are quite general, and we expect they will hold for a wide variety of
designs. The first assumption in the theorem is that the vector of stage two statistics T(2) is
independent of the stage one statistics T(1), given the enrollment decision D(T(1)) made
just after stage one. This will hold, as is the case in the class of designs from Section 3,
when the decision D(T(1)) determines a subpopulation (or the total population) to obtain
an independent random sample from in stage two, but otherwise the data in stage one has no
effect on the enrollment procedure in stage two. This conditional independence assumption
is broad enough to allow design changes such as early stopping, sample size adjustments,
and adaptation of randomization probabilities, as long as these are preplanned changes
based on statistics from stage one.
The second assumption in the theorem involves several parts, which require the intro-
duction of additional notation. Recall that P (n), the joint distribution of the statistics T,
depends on the data generating distribution Q ∈ Q and the sample size n. For any Q ∈ Q
and sample size n, denote the mean under P (n) of the first stage statistics T(1) by µ(1)n (Q),
and denote the distribution of the centered, stage one statistics T(1)−µ(1)n (Q), by G(1)n (Q).
We assume, for anyQ ∈ Q, thatG(1)n (Q) converges under P (n) to a zero mean, multivariate
normal distribution G(1)(Q) as sample size n→∞.
We assume the vector of stage two, centered statistics, conditioned on the enrollment
decision D(T(1)), converges to a multivariate normal distribution. To make this precise,
for any Q ∈ Q, for each potential stage two enrollment procedure  ∈ E , let µ(2)n (Q, )
denote the conditional mean under P (n) of stage two statistics T(2) given D(T(1)) = .
Also, let G(2)n (Q, ) denote the conditional distribution under P (n) of the centered statistics
T(2)−µ(2)n (Q, ) given D(T(1)) = . We assume for any Q ∈ Q and  ∈ E , that G(2)n (Q, )
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converges to a zero mean, multivariate normal distribution G(2)(Q, ) as sample size n →
∞. We allow the covariance of this limit distribution to depend on the data generating
distribution Q.
We furthermore assume the above convergence of centered stage one and stage two
statistics is uniform over data generating distributions Q ∈ Q. That is, we assume for all
possible enrollment decisions  ∈ E ,
lim
n→∞
sup
Q∈Q,C∈C
∣∣∣∣∫
C
d(G(1)n (Q)×G(2)n (Q, ))−
∫
C
d(G(1)(Q)×G(2)(Q, ))
∣∣∣∣ = 0, (10)
where C denotes the set of all Borel measurable, convex subsets of Rt1+t2 . In many cases,
such as the class of designs from Section 3, the above uniform convergence can be obtained
immediately from uniform central limit theorems such as those in (Go¨tze, 1991).
5.6 Intuition behind theorem
The theorem below reduces the problem of computing asymptotic, worst-case, familywise
Type I error to a more manageable optimization problem. We present some of the intuition
behind the theorem. We consider designs where the only way in which the outcomes for
subjects in stage one impact the design in stage two is through the enrollment decision
D(T(1)). Though this is not a requirement of the theorem below, which only requires the
assumptions of the previous sections, it is easier to explain the intuition for such designs.
A familywise Type I error occurs if the vector of statisticsT falls in the rejection region
corresponding to a null hypothesis that is true. In our notation above, this event can be
written as T ∈ ⋃j:Q∈H0j Rj . We partition this event into more manageable pieces by
intersecting it, for each possible stage two enrollment procedure  ∈ E , with the event that
our decision rule D says to enroll using . Define each such intersection by
A =
{
T(1) ∈ D−1() & (T(1),T(2)) ∈ ∪j:Q∈H0jRj
}
. (11)
By construction, on each such event A, the enrollment decision D(T(1)) after stage one is
always . It follows that the probability of A when T is generated by the adaptive design
is the same as the probability of A were T instead generated by the fixed design that
always makes enrollment decision  regardless of the stage one data. Thus, by taking the
intersection with each possible enrollment decision, we reduce the problem of computing
familywise Type I error for an adaptive design to that of computing it for several fixed
designs, which immensely simplifies our computations.
Combining the above with the assumption from Section 5.5 that the centered statistics
converge to a multivariate normal, we succeed in reducing the original problem to one of
computing, for each element of a class of easy to describe regions, the probability that
a zero mean, multivariate normal distribution falls in that region. These regions are the
ones in braces in (11), except that we need to center them (since we will be using centered
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statistics); we define the centered versions of these regions, for each possible enrollment
decision  ∈ E , by
V (Q, n, ) =
((
D−1()× Rt2)⋂(∪j:Q∈H0jRj))− (µ(1)n (Q), µ(2)n (Q, )) ,
where for any set B ⊆ Rk, and vector v ∈ Rk, we define the shifted version of B as
B − v = {x ∈ Rk : x+ v ∈ B}. We next present our main theorem.
Theorem 1 (Equivalence of asymptotic, worst-case, familywise Type I error to the solution
of an optimization problem) For any two stage design that adheres to the specifications in
Section 5.2, under the assumptions given in Sections 5.3 and 5.5, we have
lim
n→∞
sup
Q∈Q
∣∣∣∣∣∣P (n)
T ∈ ⋃
j:Q∈H0j
Rj
−∑
∈E
∫
V (Q,n,)
d
(
G(1)(Q)×G(2)(Q, ))
∣∣∣∣∣∣ = 0.
which implies the asymptotic, worst-case, familywise Type I error equals
lim sup
n→∞
sup
Q∈Q
∑
∈E
∫
V (Q,n,)
d
(
G(1)(Q)×G(2)(Q, )) . (12)
The expression (12) is an optimization problem, which involves finding the maximum
value of the sum in the previous display, over the class of possible data generating dis-
tributions Q ∈ Q, and computing its lim sup as sample size n goes to infinity. A key to
solving this optimization problem is that the limit distributions G(1)(Q), G(2)(Q, ) and the
set V (Q, n, ) often depend on the distribution Q only through a small number of scalar
parameters. This simplifies the computation of the inner supremum in (12) to finding the
supremum over the set of possible values of these scalar parameters. Evaluating the inte-
gral in (12) at a particular Q, n, and  is often easy, using standard functions in statistical
software for computing the distribution function of a multivariate normal distribution.
For the class of designs from Section 3, we show in Section C of the Supplementary
Material that the expression inside the lim supn→∞ in (12) has the same value for every
sample size n; this makes evaluation of (12) even easier. We conjecture that for many
designs, the value of the expression inside the lim supn→∞ in (12) will either not depend
on n or will have an easy to prove limit as n→∞, though this is an open question requiring
future research.
5.7 Application of theorem to class of enrichment designs from Sec-
tion 3
We now give an overview of how, in Sections C-E of the Supplementary Materials, we
apply the above theorem to the class of enrichment designs in Section 3, to show each of
these designs strongly controls asymptotic, familywise Type I error at level 0.05. We do
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this under the assumptions in Section 3.2, and where the rejection threshold in the final
test statistic (8) is set to Φ−1(0.95) (which is the same threshold used in the corresponding
fixed design). Below we emphasize the main ideas in applying our method. Full details are
given in Sections C-E of the Supplementary Material.
We first verify the conditions of the theorem hold for the class of enrichment designs in
Section 3. It is straightforward to verify the class of enrichment designs meets the criteria
given in Section 5.2 for which aspects of the design must be prespecified. The assumptions
in Section 5.3 follow from those in Section 3.2. It remains to verify the two assumptions
from Section 5.5. The first assumption follows since by construction, the stage two data
only depend on the stage one data through the decision D(T(1)) of which subpopulation
(or the total population) to enroll in stage two. The second assumption from Section 3
follows by applying the multivariate Berry-Esseen central limit theorem of (Go¨tze, 1991),
as described in Section C of the Supplementary Materials. Having verified the assumptions
required by the theorem, we can now apply it.
The above theorem implies the asymptotic, worst-case, familywise Type I error for each
designD in the classD in Section 3 equals the integral (12). (In (12), the regions V (Q, n, )
and the limit distributions G(1)(Q) and G(2)(Q, ) implicitly depend on the decision rule
D.) In Section C of the Supplementary Materials, using properties of multivariate normal
distributions, we show that for fixed Q, n, , the integral nested inside (12) equals the prob-
ability that a certain bivariate normal distribution falls in the region [0,∞) × [0,∞); we
show the mean and covariance of this bivariate normal distribution are simple functions
of the sample size n, the enrollment decision , the first stage enrollment proportions p
for each subpopulation, and the means and variances of the subpopulation and treatment
specific outcome distributions in Q. This has two advantages. The first is that the inner
supremum in (12) can be recast as the supremum over a finite dimensional space; the sec-
ond is that for each point in this space, the integral in (12) can be computed directly from
the multivariate normal distribution function. For example, the package mvtnorm can be
used in R to compute this.
We have reduced the problem of evaluating (12) to finding the supremum of an easy
to compute function over a finite dimensional space. We upper bound this supremum by
combining a grid search over this space with an analytic upper bound on the approximation
error of the grid search. The grid search involves computing the value of the summation
in (12) at each point in a given grid; we do this using a simple program in R, given in
Section D of the Supplementary Materials. We are able to select the size of the grid to be
sufficiently large and the distance between neighboring grid points to be sufficiently small
that the maximum value found in the corresponding grid search plus an upper bound on
the approximation error is no more than 0.05. This implies that (12) is at most 0.05. It
is straightforward to show this bound is sharp. Full details and R code are given in the
Supplementary Materials.
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6 Discussion
A limitation of our results is that they are asymptotic, that is, our guarantees on Type I error
control are in the limit as sample sizes in both stages of the adaptive design go to infinity.
However, even in fixed designs, the standard t-test comparing means in the treatment and
control groups has this issue; it is only guaranteed to have correct Type I error for testing
null hypotheses such as those in Section 3, in the limit as sample size goes to infinity (unless
parametric or other assumptions are made on the data generating distribution).
One important issue we did not address is the potential loss of generalizability in de-
signs that focus on particular subpopulations. There is a risk that such designs will lead to
conclusions applicable to a smaller population than a fixed design would have. However,
an advantage of the above adaptive designs is that when treatments are truly only effective
for one subpopulation, adaptive designs can have more power to discover this.
An area of future work is deriving the bias and mean squared error of maximum like-
lihood estimators for the adaptive designs considered in this paper. Also, methods for
constructing confidence intervals are important for such designs. Important related work
in this area includes (Jennison & Turnbull, 1984, 1989; Proschan & Hunsberger, 1995;
Lehmacher & Wassmer, 1999; Brannath et al., 2006; Wu et al., 2010). It is an open prob-
lem to determine the asymptotic, worst-case bias and mean squared error, as well as to
construct confidence intervals that are guaranteed to be asymptotically conservative.
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